Mitchell Steven Anscher, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Duke University School Of Medicine - Durham NC
Rank: Assistant Professor
Years: 1987-1994

Duke University School Of Medicine - Durham NC
Rank: Associate Professor
Years: 1994-2000

Duke University School Of Medicine - Durham NC
Rank: Full Professor
Years: 2000-2006

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Full Professor
Years: 2006-2016

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Professor Emeritus
Years: 2016-present

None Reported

Identification of M6P/IGF2R as a tumor suppressor gene in lung cancer.
Int J Radiat Oncol Biol Phys
42 (suppl 1)
Date: 01 1998

TGF beta antagonists as a potential modifier of radiation response
Radiother Oncol
48 (suppl 1)
Date: 01 1998

High-doseaccelerated radiotherapy for non-small cell lung cancer: 7360 cGy and beyond.
Int J Radiat Oncol Biol Phys
45 (suppl)
Date: 01 1999

Radiotherapy for a rising prostate specific antigen (PSA) after radical prostatectomy: the first 10 years.
Int J Radiat Oncol Biol Phys
45 (suppl)
Date: 01 1999

The potential for antagonists of TGF beta to protect against radiation induced normal tissue injury.
Int J Radiat Oncol Biol Phys
Volume: 46
Date: 01 2000

The use of TGF beta antagonists to modify normal tissue response to cancer treatment.
Radiother Oncol
56 (suppl 1)
Date: 01 2000

A phase I trial of neoadjuvant hyperfractionated radiation plus gemcitabine for adenocarcinoma of the pancreas and periampullary sites.
Int J Radiat Oncol Biol Phys
Volume: 51
Date: 01 2001

Radioprotection of lungs by amifostine is associated with reduction in pro-fibrogenic cytokine activity.
Int J Radiat Oncol Biol Phys
Volume: 51
Date: 01 2001

Re: The development of erectile dysfunction in men treated for prostate cancer.
J Urol
Volume: 166
Date: 01 2001

Using changes in plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation for non-small cell lung cancer.
Int J Radiat Oncol Biol Phys
Volume: 51
Date: 01 2001